Episode 93 Multistem, A Game Changer – Interview With Gil Van Bokkelen, CEO of Athersys

Dr Gil Van Bokkelen, Ph.D., CEO, Athersys, Inc

Multistem®, a drug-like cell therapy to treat stroke with adult stem cells is developed by Athersys (ATH-er-sis), a clinical-stage biotechnology company founded by a group of leading scientists in 1995. In Episode 91, we interviewed Sharon Thomas, a survivor who experienced miraculous recovery after given multistem.

Athersys is conducting the Phase 3 clinical trials for MultiStem®. During Phase 2 trials in the U.S, the studies showed that MultiStem® could extend the treatment window for ischemic stroke patients to 36 hours, compared to the 3 or 4 hour window to treat patients with TPA. That meant individuals who may have had a stroke in their sleep, or patients who did not recognize the symptoms right away, might still have a favorable outcome with MultiStem® versus TPA.

Multistem® has obtained FDA’s Fast Track designation. It is also in Phase 3 studies in Japan. Our guest today is Gil Van Bokkelen, CEO of Athersys, who will share with us exciting progress of Multistem®.

 

Multistem, a drug like cell therapy delivered through an IV injection.

 

 

Handinhand Show

Jing is very experienced coach from on mindful healing possibility. He will no doubt update his profile soon.

You may also like...